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ABSTRACT: Advances in exome sequencing and the development of exome genotyping arrays are enabling explorations of
association between rare coding variants and complex traits. To ensure power for these rare variant analyses, a variety of
association tests that group variants by gene or functional unit have been proposed. Here, we extend these tests to family-
based studies. We develop family-based burden tests, variable frequency threshold tests and sequence kernel association
tests. Through simulations, we compare the performance of different tests. We describe situations where family-based studies
provide greater power than studies of unrelated individuals to detect rare variants associated with moderate to large changes
in trait values. Broadly speaking, we find that when sample sizes are limited and only a modest fraction of all trait-associated
variants can be identified, family samples are more powerful. Finally, we illustrate our approach by analyzing the relationship
between coding variants and levels of high-density lipoprotein (HDL) cholesterol in 11,556 individuals from the HUNT and
SardiNIA studies, demonstrating association for coding variants in the APOC3, CETP, LIPC, LIPG, and LPL genes and
illustrating the value of family samples, meta-analysis, and gene-level tests. Our methods are implemented in freely available
C++ code.
Genet Epidemiol 39:227–238, 2015. © 2015 Wiley Periodicals, Inc.
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Introduction
Variants of functional consequence, including nonsynony-
mous, splice altering, and protein truncating variants, usu-
ally segregate at very low frequency in human populations
[Abecasis et al., 2010, 2012; Marth et al., 2011; Nelson et al.,
2012].Recent advances in exomesequencingand thedevelop-
mentof exomegenotyping arrays are enabling explorationsof
their contributions to complex disease [Kiezun et al., 2012].
Association of rare variants with disease will bring biolog-
ical insights about disease processes, but standard variant-
by-variant association tests lack power when applied to these
variants. Our work builds upon three strategies to increase
the power of rare variant association studies: grouping vari-
ants by gene or functional unit, combining results across
many studies through meta-analysis, and analysis of family
samples.
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Grouping rare variants by gene or functional unit [Li
and Leal, 2008], whether with weights [Madsen and Brown-
ing, 2009] or without [Morris and Zeggini, 2010], is now
a popular strategy for rare variant association analysis [Lee
et al., 2012a,b; Lin andTang, 2011; Price et al., 2010;Wu et al.,
2011]. The approach assumes that rare variants in the same
gene or functional unit have similar functional consequences.
When the assumption is correct and rare variants in a region
are analyzed together, association signals will be clearer than
when evaluating variants individually.
A second strategy to increase power ismeta-analysis, which
increases sample size and provides a practical approach to
difficulties in data-sharing and concerns about heterogeneity
[Lin andZeng, 2010;Willer et al., 2010].Meta-analysis of sin-
gle variants has been key in establishing association between
common variants and complex diseases [Scott et al., 2007;
Willer et al., 2010]. Meta-analysis methods for rare variant
association tests have now been proposed, although these
initial proposals and their implementations have generally
C© 2015 WILEY PERIODICALS, INC.
focused on samples of unrelated individuals [Lee et al., 2013;
Liu et al., 2014; Tang and Lin, 2013].
Finally, a third strategy is to study samples of closely re-
lated individuals, increasing the odds that multiple copies
of each rare variant are observed. Family samples are key in
studies of Mendelian disorders but can also have advantages
for studies of complex traits [Laird and Lange, 2006, 2008;
Ott et al., 2011]. For example, they can be more robust to
population stratification (which may be more acute in rare
variant association studies [Gravel et al., 2011]), allow checks
for genotyping errors (improving data quality [Abecasis et al.,
2001,2002]) and can be enriched for variants of large effect
by focusing on families with multiple individuals with ex-
treme phenotypes. Early tests for family-based association
[Abecasis et al., 2000; Laird et al., 2000; Laird and Lange,
2008] focused on analysis of transmission disequilibrium,
but newer tests rely on variance component models [Chen
and Abecasis, 2007; Kang et al., 2010] to account for stratifi-
cation, resulting in tests of association that are typically more
powerful [Chen andAbecasis, 2007]. Ourwork also builds on
computational enhancements in methods for variance com-
ponent analysis, which have now been extended to samples
of unrelated individuals (using empirical kinship matrices,
estimated from genotype data) [Kang et al., 2010; Lippert
et al., 2011; Zhou and Stephens, 2012].
Here, we describe family-based association tests for rare
variants that allowanalysis of quantitative traits,withorwith-
out covariates, and show how these tests can be applied in
meta-analysis settings. Our methods are based on the insight
that gene-level test statistics can be constructed from single-
variant score statistics and estimates of the covariance be-
tween those [Liu et al., 2014]. We first analyze single variants
using efficient computational algorithms for evaluation of
variance component models [Lippert et al., 2011]. We then
develop family-based burden (weighted and un-weighted),
sequence kernel association tests (SKAT), and variable fre-
quency threshold (VT) tests. Using simulation, we show that
type I error is well controlled and compare different test-
ing approaches. As expected, SKAT tests are more powerful
when the fraction of associated variants in each gene is small
or associated rare variants have opposite directions of effect;
VT tests are more robust to the choice of allele frequency
threshold for grouping variants. Our analysis of exome chip
genotypes and from the HUNT and SardiNIA studies shows
that our methods are well calibrated and powerful enough to
identify several signals at lipid-associated loci.
There has been much recent work focused on extending
gene-level association tests to families. Examples include var-
ious family-based burden tests [De et al., 2013; Saad and
Wijsman, 2014; Schaid et al., 2013] and variance component
based tests [Chen et al., 2013; Ionita-Laza et al., 2013; Saad
and Wijsman, 2014; Schaid et al., 2013; Schifano et al., 2012;
Svishcheva et al., 2014]. A key difference in our implemen-
tation, compared to previous work [Chen et al., 2013; Saad
and Wijsman, 2014; Schaid et al., 2013; Schifano et al., 2012;
Svishcheva et al., 2014], is that we construct our gene-level
statistics using single-variant statistics as input. This allows
us to quickly re-evaluate gene-level statistics when gene defi-
nitions changes, makes it practical to implement variable fre-
quency threshold based tests, and facilitates meta-analyses.
To ensure computational efficiency in genome-wide analy-
ses, our implementation uses a score test that requires fitting
a maximum likelihood model only once (rather than a Wald
test that would require it for every gene [Saad and Wijsman,
2014]). We also focused on methods that could accommo-
date a diverse mix of family structures or even samples that
include both families and unrelated individuals. This is in
contrast to transmission-based tests, such as proposed by
[De et al., 2013; Ionita-Laza et al., 2013] that are limited to
simpler family structures and cannot account for cryptic re-
latedness. As usual, we expect transmission-based tests may
provide greater protection against stratification—but at the
cost of greatly reduced power.
We characterize settings where family studies can provide
greater power to detect rare variants with moderate to large
phenotypic consequences than studies of unrelated individu-
als. In studies of unselected samples, this is due to a “Jackpot”
effect, whereby a family samplemaymore easily includemul-
tiple copies of trait-associated rare alleles in one locus. While
for each locus, the expected number of rare alleles will be
the same in a family sample or an unrelated sample of same
size, family samples are much more likely to exceed this ex-
pectation by a large amount. Our simulations show that this
difference can have a large impact on power. All the methods
described here are implemented in freely available C++ code
and tools.
Methods
In this section, we first describe a variance component
model to handle familial relationships. Then, we describe
how single-variant association statistics and their covariance
matrices can be calculated and how gene-level association
tests can be constructed. Next, we describe meta-analytic ap-
proaches for both single-variant and gene-level association
tests. Finally, we discuss the computational cost of our pro-
posed approach and provide practical suggestions to improve
computational performance.
Modeling Relatedness
In a sample of n individuals, we model the observed phe-
notype vector (y) as a sum of covariate effects (specified by
a design matrix X and a vector of covariate effects β), ad-
ditive genetic effects (modeled in vector g and nonshared
environmental effects (modeled in vector ε). Thus,
y = Xβ + g + ε (1)
We assume that genetic effects are normally distributed,
with mean 0 and covariance 2σ2gK, where the matrix K sum-
marizes kinship coefficients [Lange, 1997] between sampled
individuals and σ2g is a positive scalar describing the genetic
contribution to the overall variance. We assume that non-
shared environmental effects are normally distributed with
mean 0 and covariance Iσ2e , where I is the identity matrix.
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To estimate K, we either use known pedigree structure to
define Kˆ [Lange, 1997] or else use the Balding-Nicols empir-
ical estimator [Astle and Balding, 2009] that uses observed
genotypes to estimate kinship as
Kˆ =
1
v
∑v
i=1
(Gi – 2f i1) (Gi – 2f i1)
T
4f i (1 – f i)
where v is the count of variants, Gi is a genotype vector
where each element encodes the number of observed minor
alleles in a particular individual, and fi is the estimated allele
frequency for the ith variant. Model parameters, βˆ, σ̂2g , and
σ̂2e , are estimated usingmaximum likelihood and the efficient
algorithmdescribed in [Lippert et al., 2011]. For convenience,
let the estimated covariance matrix of y be ̂ = 2σ̂2g K̂ + σ̂
2
e I.
Single-Variant Association Tests and Summary Statistics
Since our gene-level association tests will build on single-
variant test statistics [Chen and Abecasis, 2007], we will first
describe single-variant test statistics and their corresponding
variance-covariance matrix.
Consider the model
y = Xβ + γi
(
Gi – Gi
)
+ g + ε
This model is a refinement of Equation (1) above, adding
a scalar parameter γi to measure the additive genetic effect of
the ith variant. As usual [Lange, 1997], the score statistic for
testing H0 : γi = 0 is as follows:
Ui =
(
Gi – Gi
)T
ˆ
–1
(
y – Xβˆ
)
And the variance-covariance matrix of these statistics is as
follows:
V =
(
G – G¯
)T (
ˆ
–1
– ˆ
–1
X
(
XTˆ
–1
X
)–1
XTˆ
–1
) (
G – G¯
)
Under the null, test statistics, Ti =
U2i
Vii
are asymptotically dis-
tributed as chi-squared with one degree of freedom.
Gene-Level Association Tests for Family Samples
Using single-variant statistics Ui and their variance-
covariance matrix V, we are now ready to construct a variety
of gene-level association test statistics that combine informa-
tion across variants.
The simplest statistic for a burden test is to estimate the
average genetic effect across a series of variants satisfying
certain functional (e.g., nonsynonymous or protein truncat-
ing variants) and frequency criteria (e.g., allele frequency
<0.05). Then the rare variant burden for each individual can
be defined as a weighted sum of allele counts for variants
satisfying these criteria. Abstractly, we define the rare variant
burden as (G – G¯)w, wherew = (w1,w2, . . . ,wm)
T is a vector
of weights for each of the m variants in the gene. A regression
parameter measuring the average effect of each variant can
be estimated using the model:
y = Xβ + γ
(
G – G¯
)
w + g + ε
To test the null hypothesis γ = 0, we use a score statistic,
expressed as a function of single-variant statistics wTU with
variance wTVw.
Then the burden test statistic Tburden =
wTU√
wTVW
is
asymptotically normal with mean zero and variance
one.
Variable Threshold Tests for Family Samples
The simplest burden tests will be effective when appro-
priate frequency thresholds and functional annotation are
used to select functional variants for analysis. However, this
is challenging to do because the optimal frequency thresh-
olds will vary by gene and by phenotype [Lange et al., 2014].
One possibility is to define a test statistic that considers many
alternative frequency thresholds [Lin and Tang, 2011; Price
et al., 2010].
Following the suggestions of Price et al. [2010] and Lin
et al. [2011], we will define the variable threshold test statis-
tic as the maximal absolute value of burden test statistics
across all possible frequency thresholds,TVT = max
F
|TburdenF|,
where TburdenF =
φTFU√
φTFVφF
is the burden test statistic calculated
with frequency threshold F and φF is a vector of 0s and 1s
indicating whether a variant has allele frequency below F.
Burden statistics calculated using different frequency thresh-
olds jointly follow a multivariate normal distribution with
mean 0, and variance-covariance matrix ψij =
φTi Vφj√
φTi Vφi
√
φTj Vφj
[Lin et al., 2011].P-values can be evaluated using the cumula-
tive density function of this multivariate normal distribution
[Genz, 1992].
Sequence Kernel Association Tests
Another refinement is to use a test statistic that allows for
variants in the samegene tomodify thephenotype inopposite
directions [Chen et al., 2013; Ionita-Laza et al., 2013; Wu
et al., 2011; Yan et al., 2014]. For example, in some genes
[Abifadel et al., 2003], both gain-of-function and loss-of-
function alleles have been described and these signals might
cancel each other in a standard burden analysis. The model
for this type of test is
y = Xβ + γ
(
G – G¯
)
+ g + ε
In this alternative model, the single-variant effects γi are
assumed to follow a shared distribution, with mean 0 and
variance τwi . We test the null hypothesis of no associa-
tion using the statistic TSKAT = UTWU to evaluate whether
τ is nonzero [Chen et al., 2013; Wu et al., 2011]. As usual,
W = diag (w1,w2, . . . ,wm) is a diagonal matrix indicating
the weight of each variant. TSKAT is distributed as a mix-
ture chi-squared with weights λ1, λ2, . . . , λn corresponding
to the eigenvalues of V
1
2WV
1
2 and the χ21 (i) correspond to
independently distributed chi-squared variables, each with
one degree of freedom [Wu et al., 2011]. P-values can be
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evaluated using the Davies algorithm [Davies, 1980] or a
moment matching algorithm [Liu et al., 2009].
Meta-Analysis
Since we derived all the statistics above from single-
variant score statistics and their covariance matrix, our
approach can be readily extended to meta-analyses. We
first define the overall single-variant score statistics and
their variance-covariance matrix as Umetai =
∑s
k=1 Uik and
Vmeta j =
∑s
k=1 Vij ,k, where Uik and Vij ,k are the single-variant
score statistic and variance-covariance matrix components
from study k and s are the total number of studies. When-
ever variant i is unobserved in study k, we set Uik = 0
and Vij,k = 0 for all j. Next, we simply calculate burden,
VT, and SKAT meta-analysis statistics using the formulae
above.
Computational Efficiency
Since we rely on score statistics and their covariance, we
only need to fit the linear mixed model once under the null
hypothesis. Fitting parameters for this null mixed model is a
major part of the computational cost of our approach. Stan-
dard EM or Newton-Raphson methods require calculating
the inverse of the covariance matrix in each iteration—with
time complexity O(n3), too costly for large datasets. Instead,
we used the computationally efficient algorithm described
in Lippert et al. [2011] to estimate the variance components
and fixed effects under the null (Eq. (1)). The algorithm be-
gins with a one-time singular value decomposition (SVD) of
the relationship matrix Kˆ, a step which has time complexity
O(n3)). The results of this decomposition are used in a fac-
torization that transforms the phenotype vector and design
matrix so that transformed phenotypes are identically and
independently distributed. This second step has time com-
plexity O(n2). After transformation, the cost of updating the
log likelihood becomes linear with respect to sample size n
(instead of O(n3) using the standard approach). Calculating
the score statistics and their covariance for all single variants
simply requires a transformation of genotypes and has time
complexity O(mn2) for a dataset with m variants. In reality,
we calculate covarianceof score statistics frommarkerswithin
a sliding window. For large samples, calculating the SVD of
Kˆ is the computationally most expensive step. A similar idea
with comparable computational efficiency has also been de-
scribed in Zhou and Stephens [2012]. Both ideas build upon
the algorithm described by Kang et al. and implemented in
EMMAX [Kang et al., 2010].
When variants are grouped in gene-level tests, the com-
putational cost of calculating the combined test statistics is
small after single variants have been analyzed. Obtaining P-
values corresponding to these statistics, especially for SKAT
and VT analyses, can still be challenging when the number of
rare variants in a gene is large. To speed up this step, we used
computationally efficient algorithms to evaluate the multi-
variate normal probabilities [Genz, 1992] and the mixture
chi-squared distribution [Davies, 1980].
Simulation
We carried out a series of simulations to evaluate the per-
formance of our method. We first simulated a set of 1,000
base-pair sequences, which is close to the length of an av-
erage protein coding sequence in humans, using the coales-
cent (as implemented in the program ms [Hudson, 2002])
and a demographic model calibrated to mimic European
population history [Adams and Hudson, 2004; Novembre
et al., 2008]. We then carried out gene-dropping simulations
[Abecasis et al., 2002] using these simulated sequences as
founder haplotypes that were propagated through various
pedigree structures (Fig. 1).
To evaluate power, we assigned a fraction of variants below
a desired frequency threshold (<0.01 in simulations unless
addressed otherwise) as causal. Typically, we assigned mi-
nor alleles at causal variants to all have effects in the same
direction but, in some cases, a fraction of causal minor al-
leles was assigned effects in the opposite direction. When
assigning effect sizes to causal variants, we considered two
trait-generating models—an equal variance model (where
the effect size for each variant is proportional to 1√
p (1–p )
, a
function of the allele frequency p that ensures each causal
variant explains the same amount of trait variance) and an
equal effect-size model (where the effect size is the same for
all causal variants, irrespective of allele frequency). In the
equal effect-size model, relatively common variants explain
a larger amount of the variance; while in the equal variance
model, rarer variants have larger effect sizes (see supplemen-
tary Fig. S1 for demonstration). Genetic effects were set so
that the total variance explained by each gene (h2gene) was
in the 0.1–2% range. Empirical power was calculated using
10,000 simulations for each parameter combination.We used
α= 1× 10–8 for single-variant association power andα = 2.5×
10–6 for gene-level association power. Type I error rate for
gene-level tests was estimated using 5,000,000 simulations.
To compare studies of families and unrelated individuals,
we held the number of genotyped (or sequenced) individ-
uals constant and compared our ability to detect associated
variants in studies using different sampling units. In simu-
lations and following association analysis, kinship matrices
estimated frompedigree were used to fit the null linearmixed
model.
SardiNIA and HUNT Samples Description
To further evaluate how our method performs in real data
analysis, we used exome chip data from the HUNT [Holmen
et al., 2014a,b] and SardiNIA [Pistis et al., 2014; Pilia et al.,
2006] studies, which genotyped 5,803 and 6,602 individuals,
respectively. Here, we analyze HDL, adjusted for age and sex
(supplementary Table S3). Genotypes were called using the
Illumina GenCall algorithm in combination with zCall V2.2.
Detailed quality control (QC) procedures can be found in
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Figure 1. Pedigree structures used in simulations.
[Holmen et al., 2014a] for the HUNT study and [Pistis et al.,
2014] for the SardiNIA study.
Results
Type I Error Rate
To evaluate type I error rate, we simulated family samples
of 1,000 or 5,000 individuals with family structures matching
three-generation pedigrees with 10 (Pedigree10) or 50 (Pedi-
gree50) individuals (see Fig. 1 for details). Within each gene,
variantswith frequency <0.01were grouped for analysis. Each
type I error estimate summarizes results from 5-million sim-
ulations. Supplementary Table S1 shows that the type I error
of our gene-level association tests is well controlled for a va-
riety of pedigree structures. Empirical error rates are a little
belownominal levels when sample sizes are small (N = 1,000),
but approach nominal significance as sample size increases
(N = 5,000).
Power of Different Rare Variant Association Tests
Next, we evaluated the power of our proposed association
tests under various scenarios. We used significance level α =
2.5 × 10–6, which corresponds to Bonferroni adjustment for
testing of 20,000 genes. We first simulated samples of 5,000
individuals distributed in three-generation pedigrees with 10
individuals each (Pedigree10 in Fig. 1). Variants with minor
allele frequency (MAF) <1% (<5% where noted) explained
1% of the variance in a simulated quantitative trait. When
all associated variants had the same effect size and the pro-
portion of causal variants was small (20%), SKAT had the
largest power. When this proportion grew larger (80%),
VT became the most powerful test (Table 1). Although we
did not simulate a relationship between frequency and effect
size among causal variants, VT provided greater power be-
cause it sometimes excluded relatively common unassociated
variants from consideration, reducing noise. When fraction
of causal variants is small, methods that explicitly allow for
heterogeneity in effect sizes do better, since no correlation
between causality and effect size was simulated, VT cannot
easily exclude most of the unassociated variants. In practice,
the true list of causal variants is usually unknown; and allele
frequency is often a good proxy to identify variants likely to
modify gene function [Nelson et al., 2012]. In a simplified
scenario where only causal variants were grouped and other
variantswere discarded, the basic burden test becameoptimal
(Table 1).
We next considered more complex scenarios. When 20%
causal variants decreased trait values and the remainder
increased trait values, the power of burden and VT tests
dropped dramatically and SKAT became the most pow-
erful test, regardless of the proportion of causal variants
(Table 2). When we setup our simulation so that each vari-
ant explained the same fraction of trait variance (and, thus,
so that rarer variants had larger effects), SKAT remained the
most powerful testwhen theproportionof causal variantswas
Table 1. Power when causal variants all increase trait values and have the same effect sizes
Group by MAF cutoff Group of only causal variantsb
MAF cutoff
Causal
percentage (%) Burden
Madsen-
Browning VT SKATa Burden
Madsen-
Browning VT SKAT
0.01 20 9.7 3 13.1 36.6 94.3 86.7 92.9 82.6
80 82.4 64.7 88.1 61 96 82.1 94.3 70.7
0.05 20 14.6 2.6 24.9 36.3 95.4 75.3 93.8 86.5
80 81.3 39.5 89.2 75 96.3 55.3 94.3 82.9
Simulated samples each had 5,000 individuals, organized in families with Pedigree10 structure (see Fig. 1). Causal variants were selected among those identified in simulated
1,000 base-pair sequences and explained 1% of trait variance. Each causal variant had the same effect size and direction. Power is tabulated as a percentage of simulations
exceeding significance threshold. Significance level α = 2.5 × 10–6 was used in all simulations.
a Power calculated from Madsen-Browning weighted SKAT.
b Power when grouping only causal variants. This column represents the largest power we can achieve for each simulation setting.
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Table 2. Power comparison when causal variants can have opposite effects
Group by MAF cutoff Group of only causal variants
MAF cutoff
Causal
percentage (%) Burden
Madsen-
Browning VT SKAT Burden
Madsen-
Browning VT SKAT
0.01 20 4.6 0.4 6.0 36.7 38.9 21.1 43.4 83.2
80 30.5 10.4 33.4 60.0 42.6 18.8 42.2 69.0
0.05 20 11.7 1.3 15.0 35.7 55.4 22.3 58.3 88.3
80 44.0 7.8 47.1 74.7 55.1 12.2 54.3 81.6
Simulated samples each had 5,000 individuals, organized in families with Pedigree10 structure (see Fig. 1). Causal variants were selected among those identified in simulated
1,000 base-pair sequences and explained 1% of trait variance. Among causal variants, 20% were randomly selected to be trait-decreasing, and the rest causal variants were
trait-increasing. Power is tabulated as a percentage of simulations exceeding significance threshold. Significance level α = 2.5 × 10–6 was used in all simulations.
Table 3. Power comparison when causal variants all increase trait values and explain the same amount of trait variance
Group by MAF cutoff Group of only causal variants
MAF cutoff
Causal
percentage (%) Burden
Madsen-
Browning VT SKAT Burden
Madsen-
Browning VT SKAT
0.01 20 4.3 4.2 9.1 20.8 88.7 94.9 90.8 67.0
80 66.9 86.6 85.4 20.1 85.5 97.1 93.8 27.0
0.05 20 3.8 5.1 9.3 9.8 78.8 98.0 90.1 53.0
80 38.6 88.5 82.1 9.4 56.0 97.9 92.6 12.4
Simulated samples each had 5,000 individuals, organized in families with Pedigree10 structure (see Fig. 1). Causal variants were selected among those identified in simulated
1,000 base-pair sequences and explained 1% of trait variance. Each causal variant explained the same amount of trait variance. All causal variants were trait-increasing. Power is
tabulated as a percentage of simulations exceeding significance threshold. Significance level α = 2.5 × 10–6 was used in all simulations.
small, but theMadson-Browning (MB) weighted burden test
outperformed VT and SKAT when the proportion of causal
variants was large (80%; Table 3). This was expected since, in
this setting, relative effect sizes match those predicted by the
MB-weighting scheme.
Power When Misspecifying Frequency Threshold
Wenext investigated the impact ofmisspecifying frequency
thresholds during analysis. Supplementary Figure S2A shows
that when causal variants have the same effect sizes, VT and
MB-weighted burden tests perform well as long as the fre-
quency cutoff used during analysis is larger than the cutoff
used for simulation. In contrast, the power of SKAT and sim-
ple burden tests is greatly reduced when incorrect frequency
thresholds are used for analysis. Supplementary Figure S2B
shows that when rare causal variants have larger effects and
all variants explain the same amount of trait variance, all tests
reach maximum power at a frequency threshold less than or
equal to 0.01, the threshold for simulating causal variants.
Whereas the power of VT and MB remain close to optimal,
the power of SKAT and the simple burden tests drops greatly
as the frequency threshold used for analysis increases and
noncausal and small effect variants enter the analysis. In real
data analysis, because true disease model is unclear, we rec-
ommendmultiple frequency thresholds should be usedwhen
using SKAT or simple burden tests [Lange et al., 2014].
Relative Power of Family Samples and Unrelated
Individuals
We used simulations to compare the benefits of samples
of families and unrelated individuals in association studies.
Family samples can allow many copies of the same trait-
associated rare alleles to be observed in a single study. Vari-
ability in allele counts is larger in families, particularly inpedi-
grees with many descendants for each founder. For example,
for a variant with allele frequency 0.0005 (approximately five
alleles expected when 5,000 individuals are sequenced), the
standard deviation of the allele counts in a sample matching
Pedigree50 (from Fig. 1) is greater than three times larger
than a sample of unrelated individuals (see supplementary
Table S2 for details)—meaning that the chance of observ-
ing >10 copies of the variant is 20% when families match-
ing Pedigree50 are sampled, but 4% in samples of unrelated
individuals.
We speculated that the increased variability in allele counts
in family samples would mean that family samples might
sometimes hit a “jackpot” and sample many copies of a
trait-associated rare allele, increasing power. This specula-
tion was supported by our simulations: a sample of 5,000
individuals in families matching Pedigree50 provides greater
than twofold greater power to detect a variant with frequency
0.001 and effect size 1 than a population sample of the same
size (power was 0.9% in sample of unrelated individuals and
2.3% in sample of families, supplementary Fig. S3). This in-
crease may seem paltry, but it is important to remember that
many susceptibility loci underlie each human complex trait:
if there are hundreds of such loci and power increases from
0.9% to 2.3% at each of those, the odds of a successful dis-
covery will increase dramatically. The idea of “jackpot” effect
was also supported by close examination of our simulation
results. Among all 10,000 simulated samples, the average fre-
quency of trait-associated alleles was 0.0010, but in samples
that have association P-value <1 × 10–8, the frequency of
trait-associated alleles was higher, averaging 0.0032, a greater
than threefold increase. The relative advantages of family
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Figure 2. Power to detect gene-level association in family and pop-
ulation samples. All samples had 5,000 individuals. All family samples
used thePedigree50 structure (see Fig. 1 for details). In every simulation,
10,000 haplotypes were simulated and 20% of variants with MAF < 0.01
were randomly selected as causal variants, each explaining the same
amount of trait variance. Then, a subset of simulated haplotypes was
selected as founder haplotypes, segregated through families according
to Mendel’s laws, and used to simulate quantitative traits. Power of the
SKAT test was evaluated using 10,000 simulations and significance level
α = 2.5 × 10−6.
samples over unrelated samples decrease in settings where
power (and, typically, the number of expected rare allele car-
riers) is high. For example, when sample size increases, allele
frequency increases, or effect size (or variance explained)
increases unrelated samples quickly become more powerful
(supplementary Fig. S3).
Consistent to patterns in single-variant association power,
Figure 2 shows that family studies have the similar advantages
in studies of gene-level rare variant associations. For exam-
ple, in a sample of 5,000 individuals, power to detect a gene
where 20% of variants with frequency <1% are causal and
explain 0.5% trait variance increases from 1% for unrelated
individuals to 13% for family samples.
Advantages in power from studies of families are strongly
correlated to the variance of allele counts (which is a function
of family size and pedigree structure). For example, a sample
of families matching Pedigree50 (Fig. 1) has largest variance
in allele counts (supplementary Table S2) and also the largest
power for detecting a gene explaining 0.5% of trait variance
in a sample of 5,000 individuals (Fig. 3), whereas a sample
of families matching Nuclear4 (Fig. 1) has the smallest vari-
ance in allele counts and provides the smallest increase in
power relative to samples of unrelated individuals (in this
simulation, 20% of variants with frequency 1% were causal).
All family samples have larger variance in allele counts than
unrelated samples.
Figure 3. Power to detect gene-level association as a function of
pedigree structure. In each simulation, 20% of variants with MAF < 0.01
were randomly assigned as causal, each explaining the same amount of
trait variance. Together, causal variants explained 0.5%of trait variance.
For comparison, the red line shows the power for one variant with
frequency of 0.5 and explaining 0.5% of the trait variance. Power of the
SKAT test was evaluated using 10,000 simulations and significance level
α = 2.5 × 10−6.
The advantage of family samples extends to extremely rare
variants. Figure 4A shows thatwhen20%of singletonvariants
(defined as alleles present only once in our initial pool of
10,000 simulated sequences) in a gene were causal explaining
0.5% trait variance, power to detect gene-level association
increaseddramatically from3.5%ina studyof 5,000unrelated
individuals to as much as 19.3% in a study of 5,000 related
individuals. Figure 4B shows that when sample size increase
to 10,000 individuals, the window where family samples are
more advantageous becomes narrower.
In all examples highlighted so far, family studies outper-
form studies of unrelated individuals but in all of these ex-
amples power was low for both families and unrelated indi-
viduals. We expect that this is actually a common situation
in human genetic studies—there may be very large numbers
of trait-associated loci but any single study may only provide
enough power to detect a few of these. To explore this situ-
ation directly, we estimated power to detect at least one of
several disease-associated loci. Assuming power to detecting
association at a specific gene is p and x genes with similar
effect variants exist, then the power to detecting at least one
of these is 1 – (1 – px), assuming independent genes. Figure 5
shows dramatic advantages in the power to detecting at least
one of 20 trait-associated genes, each explaining the same
proportion of trait variance. For example, power to detect-
ing at least one gene explaining 0.5% trait variance (when
20% variants in the gene and with frequency <1% are causal)
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Figure 4. Power to detect gene-level association when singletons are causal. In each simulation, 10,000 simulated haplotypes were simulated.
Twenty percent singletons from these haplotypes were chosen as causal variants, together explaining various proportions of trait variance. Trait
heritability was 40%. Then, a subset of haplotypes was used to seed founder haplotypes in each family sample. Only singletons or private variants
were grouped for association tests. A total of 10,000 simulations were used to evaluate power in samples of 5,000 individuals (panel A) or 10,000
individuals (panel B). See Figure 1 for details of pedigree structures. Power was evaluated in 10,000 simulations using significance level α = 2.5 ×
10−6.
Figure 5. Power to detect at least one of 20 causal genes. Assuming
power to detect association at a specific gene is p and n genes with
similar effect variants exist, then the power to detect at least one of
these is 1 − (1 − p)n. See Figure 2 for power to detect a single gene and
additional details of simulation settings.
when 20 such genes exist is >90% in sample of 5,000 indi-
viduals distributed in families matching Pedigree50 (Fig. 1),
whereas only20% in a sample of 5,000 unrelated individu-
als. The power advantage in family samples increases with the
variability in allele counts, which in turn is driven by pedigree
structure (Fig. 6).
Figure 6. Power todetect at least oneof 20 causal genesasa function
of pedigree structure. The blue bars show power to detect at least one
gene where rare variants explain 20% of trait variance and 20 such
genes exist. See the legends of Figure 3 for simulation settings. See the
legends of Figure 5 for calculating power to detect at least one of n
genes with similar effect variants exist.
Families matching Pedigree50 are not easy to find. For a
more realistic comparison of the power of studies of fami-
lies and unrelated individuals, we repeated our simulations
using the family structures and phenotypes observed in the
SardiNIA sample. To preserve the correlation of phenotypes
among family members, we started with observed HDL
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values together with sex, age, and age-squared as covari-
ates. Supplementary Figure S4 shows that the SardiNIA fam-
ilies provide larger power for discovering rare variants with
moderate effect sizes than studies of same numbers of un-
related individuals. For example, the SardiNIA sample pro-
vides 1.6% power to detect a variant with frequency 0.0001
and effect of 2.5 trait standard deviation units, whereas unre-
lated samples provide only 0.05%power (supplementary Fig.
S4A). If 100 such variants exist, the SardiNIA sample provides
80% power to detect at least one, but an equal number of
unrelated individuals provides only 5% power to detect at
least one of such a variant (supplementary Fig. S4B). When
allele frequency increases (supplementary Fig. S4C–F), the
SardiNIA sample is still advantageous when effect sizes are
moderate.
Real Data Analysis Using SardiNIA and HUNT Studies
To evaluate our approach further, we meta-analyzed blood
HDL levels for 11,556 individuals from the HUNT and Sar-
diNIA studies (see supplementary Table S3 for descriptive
statistics for traits). Overall, 93,831 and 76,828 sites were
polymorphic in the HUNT and SardiNIA studies, respec-
tively, resulting in 117,958 polymorphic variants when com-
bining the two studies (supplementary Table S4). Among
those, 52,700 variants were shared in both studies (supple-
mentary Table S5), 41,130 variants are unique to the HUNT
study, and 24,128 variants are unique to the SardiNIA study
(supplementary Table S6). Using our meta-analysis method,
both shared and nonshared variants contribute to association
signals.
Wefirst generated summary statistics for each study adjust-
ing for relatedness using empirical kinshipmatrices estimated
from genotype data. Within each sample, test statistics were
well calibrated with genomic control 1.00 in HUNT study
and 1.01 in SardiNIA sample (see supplementary Fig. S5 for
QQ plots). To illustrate the importance of taking into ac-
count phenotype correlations, consider that analyzing the
SardiNIA exome chip data and treating the samples as un-
related results in a genomic control value of 1.45, which is
unacceptably high (results not shown); but using our ap-
proach, genomic control becomes 1.01. We next proceeded
to meta-analyze single variants. Supplementary Figure S5
shows that our meta-analysis statistics were also well cali-
brated with genomic control value <1.05, both for common
and rare variants. At a significance threshold of P < 4.23 ×
10–7 (corresponding to 0.05/117,958), we found significantly
associated low-frequency and rare variants at CETP, LIPC,
LIPG, and LPL for HDL (MAF < 5%; see supplementary
Fig. S6 for Manhattan plots). Significant rare variants were
only found in LIPC and LIPG (MAF < 1%).
We then proceeded to gene-level meta-analyses. Again, test
statistics appear well calibrated, with genomic control value
<1.05 (see supplementary Fig. S7 for QQ plots). Also, by ex-
amining QQ plots from SardiNIA and HUNT studies (see
supplementary Fig. S7), we discovered that, for family sam-
ples or samples from isolated population, in the analysis of
rare variants, a small number of individuals can be quite in-
fluential such that all variants that are shared between this
set of individuals (or families) will exhibit similar and often
small P-values. This can lead to apparent inflation in QQ
plots, where confidence intervals are calculated assuming all
statistics are independent. At a significance threshold of P <
2.84 × 10–6 (corresponding to 0.05/17,574 and thus allow-
ing for the number of genes tested), we found association at
APOC3, CETP, LIPC, LIPG, and LPL for HDL (see Table 4 for
tabulated results and supplementary Fig. S8 for Manhattan
plots). Among those,APOC3, LIPG, and LPL had evidence of
association stronger than the most significant single variant
in the region. In APOC3, none of the individual low fre-
quency and rare variants had P-value lower than 10–4 on its
own (Table 4).
Comparison with Other Methods and Tools
To validate our approach, we compared our implementa-
tion to several others in a simulated family sample of 10,000
individuals distributed across 1,000 families matching Pedi-
gree10 (see Fig. 1). A total of 4,000 genes with 1,000 base-pair
were simulated in families from a pool of haplotypes. A quan-
titative trait was simulated under the null. Variants withMAF
< 0.05 were grouped for gene-level tests. Pedigree-based kin-
ship matrices were used in all analyses. We then analyzed the
simulated sample using our own famrvtest (SKAT, burden,
and VT tests), pedgene (burden and kernel tests) [Schaid
et al., 2013], famSKAT [Chen et al., 2013], and FFBSKAT
[Svishcheva et al., 2014]. Supplementary Figure S9 shows
that all tests generate well-controlled QQ plots under the
null.
To compare methods under the alternative, we simulated
a dataset of 5,000 individuals (500 × Pedigree10) where a
1,000 base-pair long gene where 50% variants with MAF <
0.05 were causal and together explained 1% trait variance.
We simulated datasets where all causal variants had the same
direction and also where half of the causal variants had oppo-
site effects. In this simulation, our method always matched
or slightly outperformed alternative implementations (see
supplementary Fig. S10).
These comparisons also allowed us to evaluate computa-
tion performance and requirements for our tool. Wherever
possible, we tried to provide faster computation, less mem-
ory use, while still allowing for flexible input formats and
varied choices of association tests. famrvtest implemented
in a C++ command line tool uses computationally efficient
algorithms to fit linear mixed models [Lippert et al., 2011],
and recognizes pedigree-based kinship estimates as block-
diagonal matrices to save computational effort. For our sim-
ulated dataset with 10,000 individuals and 164,323 variants
distributed across 4,000 genes, analysis with famrvtest re-
quired 1.5 hr and 1.3 GB of memory to calculate both SKAT
and burden test statistics, a savings of up to 10- to 100-fold
relative to alternative tools (see supplementary Table S7).
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Table 4. Significant genesa from gene-level meta-analysis of HUNT and SardiNIA exome chip data (HDL)
Gene Burden Madsen-Browning VT (actual MAF cutoff) SKATc Variants includedd MAF Effect sizes (SD) Single-variant P-values
APOC3b 2.3 × 10–6 1.9 × 10–6 6.4 × 10–6 (6.1 × 10–4) 4.5 × 10–5 11:116701560:G:A 4.8 × 10–4 0.959 1.4 × 10–3
11:116701353:C:T 5.6 × 10–4 1.009 1.5 × 10–3
11:116701354:G:A 6.1 × 10–4 0.528 5.7 × 10–2
CETP 6 × 10–20 2.7 × 10–3 2.4 × 10–19 (3.2 × 10–2) 1.2 × 10–20 16:57015091:G:C 3.2 × 10–2 –0.359 1.3 × 10–20
16:57007387:C:T 4.3 × 10–5 2.241 2.3 × 10–2
16:56995935:C:G 4.3 × 10–5 –1.572 1.1 × 10–1
16:57012039:G:A 4.3 × 10–5 –0.803 4.2 × 10–1
16:57009022:G:A 1.7 × 10–4 0.309 5.3 × 10–1
16:57015076:G:A 2.2 × 10–4 0.144 7.4 × 10–1
16:57012094:A:G 4.3 × 10–5 0.182 8.5 × 10–1
LIPGb 1.3 × 10–10 6.7 × 10–9 4.5 × 10–10 (9.4 × 10–3) 1.9 × 10–8 18:47109955:A:G 9.4 × 10–3 0.375 4.5 × 10–8
18:47113165:C:T 9.1 × 10–4 0.668 2.3 × 10–3
18:47109939:G:A 1.7 × 10–4 1.012 3.9 × 10–2
18:47101838:G:A 4.3 × 10–5 1.000 3.1 × 10–1
LPLb 3.7 × 10–11 4.5 × 10–5 1.2 × 10–10 (2.0 × 10–2) 2 × 10–11 8:19813529:A:G 2.0 × 10–2 –0.273 1.3 × 10–8
8:19805708:G:A 1.1 × 10–2 –0.254 7.5 × 10–5
8:19816888:C:T 1.1 × 10–3 0.234 2.3 × 10–1
8:19819628:T:G 4.3 × 10–5 0.193 8.4 × 10–1
LIPC 1.8 × 10–4 1.5 × 10–4 3.2 × 10–5 (6.2 × 10–3) 1.7 × 10–7 15:58855748:C:T 6.2 × 10–3 0.539 4.9 × 10–10
15:58837989:G:A 7.4 × 10–4 0.542 2.5 × 10–2
15:58833993:G:A 3.1 × 10–2 0.054 1.7 × 10–1
15:58830716:G:A 8.7 × 10–5 0.123 8.6 × 10–1
15:58853079:A:C 5.9 × 10–3 –0.003 9.8 × 10–1
15:58860956:G:A 4.3 × 10–5 0.025 9.8 × 10–1
a Significance level 2.84 × 10–6 was used for reporting significant genes. Nonsynonymous, splice, and stop variants with MAF < 0.05 were included in analysis.
b The gene-level P-value is smaller than the P-value for each of the single variants included in the test.
c P-values of SKAT were generated using weights suggested in Wu et al. [2011].
d Variants are in the following format: CHR:POS:REF:ALT.
Discussion
Gene-level association tests and meta-analysis are impor-
tant tools for discovering rare variant associations. We have
proposed a series of methods that facilitate these analyses
in family samples (or in samples where cryptic relatedness
is modeled using variance components). Our C++ tools im-
plement simple burden tests, weighted or un-weighted; and
variable threshold tests as well as SKAT tests that outperform
other tests when only small fractions of variants in each gene
are causal or when variants with opposite effects reside in the
same gene.
We compare the relative benefits of family samples and
population samples. By simulation, we show that family sam-
ples can provide substantially greater power for rare variant
association studies because of a “jackpot” effect—the po-
tential for observing many copies of a trait-associated rare
variant. This advantage is likely to be extremely important
in the first generation of rare variant association studies,
each of which is only expected to detect a small fraction of
all the true rare variant association signals. An example of
successful discovery of such variant is rs72658864/V578A in
gene LDLR, a rare variant associated to LDL with effect size
23.7 mg/dl [Sanna et al., 2011]. This variant was observed
with frequency 0.00035 in the SardiNIA sample, where it was
present in multiple families, but has not yet been observed
in the 1000 Genomes [Abecasis et al., 2012] or the NHLBI
Exome Sequencing Projects [Fu et al., 2013; Tennessen et al.,
2012] suggesting that it is rare indeed.
We demonstrate the utility of our methods by analyzing
two samples with complex interrelatedness. Meta-analysis of
SardiNIA and HUNT resulted in a well-calibrated genomic
control value of 1.02 and increased signal atmany loci known
to be associated with HDL—demonstrating the feasibility of
including family samples in rare variant meta-analysis. We
expect that meta-analysis will be useful not only for com-
bining data across studies but also to facilitate analysis of
large samples genotyped or sequenced across multiple plat-
forms or analyzed using a single platform but in a batched
manner.
We foresee several potential areas for refinement of our
methods. For example, a limitation for our current approach
to meta-analysis is that cross-study relatedness and sample
overlap are not modeled. In genome-wide studies, it may be
possible to overcome this limitation by using the genome-
wide correlation of test statistics between pairs of studies to
calculate an adjustment factor that could account for overlap
or relatedness between individuals in two studies [Lin and
Sullivan, 2009]—as suggested by [Lin et al., 2011] for single
marker meta-analyses. Extension of this idea has also been
proposed in [Han et al., 2013]. Extending our methods to
noncoding variants will also be attractive, particularly since
the majority of trait-associated variants found to date are
located in noncoding regions. A difficulty will be the devel-
opment of good grouping strategies for noncoding variants,
where interpretation of functional consequence is more chal-
lenging. Another challenge we foresee is the extension of our
methods to discrete traits. The natural way to do this is to
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consider an underlying continuous liability scale and use
multivariate integration to fit the model, but there may be
more computationally efficient alternatives to be discovered.
In summary, we have proposed a series of gene-level as-
sociation tests for family samples and methods for cal-
culating these in a meta-analysis of related and/or unre-
lated samples. We also implemented our methods in freely
available and open source C++ tools: http://genome.sph.
umich.edu/wiki/FamRvTest and http://genome.sph.umich.
edu/wiki/RAREMETAL. We hope these tools and methods
will facilitate the next round of gene-mapping studies.
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